Cardiff Oncology Inc. (CRDF)
NASDAQ: CRDFHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CRDF stock chart
Technical analysisKey statistics
All statistics- Market cap
- $84.02M
- EPS (TTM)
- -$0.60
- Dividend yield
- None
- 52-week range
- 0.76 – 3.31
- Day range
- 1.06 – 1.11
- Volume / Avg
- 297.23K / 1.05M
- Beta
- —
- Shares outstanding
- 77.80M
- Next earnings
- Nov 5, 2026
52-week range
CRDF stock today
Shares of Cardiff Oncology (CRDF) finished higher on Oct 9 at $1.08, a gain of 1.89% or $0.02 per share, versus the S&P 500's 0.59% gain. Trading was light, with 297.23K shares changing hands, about 28% of the average daily volume. Shares are 67.4% below their 52-week high of $3.31, set on Dec 26, 2025 and 42.1% above the 52-week low of $0.76, near the bottom of the past year's range.
CRDF is down 61.6% year to date, underperforming the S&P 500 (+14.2%). Over the past 12 months, the stock has lost 54.6%. Cardiff Oncology has posted a net loss over the last twelve months (EPS of -$0.60), so its P/E ratio is not meaningful. Cardiff Oncology's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Cardiff Oncology
Company profileCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Mani Mohindru Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 30
- Website
- cardiffoncology.com
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$5.81+437.96%
- Strong buy 1
- Buy 2
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.14
Cardiff Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CGTXCognition Therapeutics Inc. | 0.8769 | -2.04% | $83.39M | vs CRDF |
| PTHSPelthos Therapeutics Inc. | 20.50 | 0.00% | $78.48M | vs CRDF |
| NMRANeumora Therapeutics Inc. | 0.4757 | -0.85% | $89.38M | vs CRDF |
| OKYOOKYO Pharma Limited | 1.42 | +2.16% | $74.52M | vs CRDF |
| ATRAAtara Biotherapeutics Inc. | 9.48 | +2.71% | $95.16M | vs CRDF |
| GRMLGreenland Mines Ltd. | 5.17 | -12.07% | $69.00M | vs CRDF |
| CSBRChampions Oncology Inc. | 4.84 | -2.81% | $67.37M | vs CRDF |
| BDTXBlack Diamond Therapeutics Inc. | 1.83 | +1.10% | $104.86M | vs CRDF |
Indexes, lists and sector
Cardiff Oncology stock FAQ
What is Cardiff Oncology's stock price today?
CRDF last traded at $1.08 as of Oct 9, 4:00 PM EDT, up 1.89% on the day. Prices are delayed at least 15 minutes.
Does Cardiff Oncology pay a dividend?
No. Cardiff Oncology does not currently pay a regular cash dividend.
When is Cardiff Oncology's next earnings date?
Cardiff Oncology is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.14.
Who is Cardiff Oncology's CEO?
Dr. Mani Mohindru Ph.D. is the chief executive officer of Cardiff Oncology Inc., which has about 30 employees.
Has CRDF ever split its stock?
Yes. The most recent CRDF stock split was a 1-for-6 split on Feb 20, 2019, one of 4 splits on record.
What is the CRDF 52-week high?
The 52-week high for CRDF is $3.31 and the 52-week low is $0.76. The stock is currently 67.4% below its high.